Drug Delivery System for Nasal MRSA Eradication

main content

Background

MRSA (methicillin resistant S. aureus) is a potential killer infection that is endemic in our hospitals. Around 20% of the general population (patients, staff, hospital visitors) are believed to be carriers with potential to cause infection. 

Recent focus on cleanliness in hospitals and introduction of antiseptic handgels in wards has been partially successful in reducing infection.  However, S.aureus is carried by the general population in their nasal passages (including patients, staff and visitors to our hospitals) which is not addressed by handwashes. Further, existing nasal treatments have inherent problems of rapid clearance due to mucocillary action and have failed to stop the spread of MRSA.

Technology

A research team at the University of Strathclyde has demonstrated that the use of novel formulations results in rapid adherence to the nasal mucosa by formation of viscous gels that resist removal by cilia. A sustained absorption profile is obtained, leading to reduced frequency of dosing. The novel nasal formulations (NNF) are virtually sensation free and afford prolonged residence in man.

Key Benefits

  • Reduction in MRSA infections in hospitals
  • Decreased lengths of hospital stay
  • Prevention of healthcare associated infections
  • Technology can be applied to a wide spectrum of drug
  • Cleaner and more convenient to use than creams or ointments
  • Prolonged duration of action avoids the repeat dosing required by current products

Markets and Applications

The novel nasal formulations could be used to treat the entire patient, staff and (perhaps) visitor population frequenting our hospitals. This could mean the treatment of in excess of 150,000 staff and a significant number of the 1.6 milllion elective stay patients in the UK. This technology could also be applied to many other drugs and therapeutic situations.

Licensing and Development

The technology is a novel finding that constitutes a patentable invention. The IP is protected through non-disclosure and contact is welcomed from organisations interested in developing or exploiting this technology. Please contact ri@strath.ac.uk quoting reference number 1683.

 

Contact Information

For further information please contact the Knowledge Exchange Hub:

0141  548 4759

ke-hub@strath.ac.uk

If your query relates to medical devices, please contact

 

Contact us

For further information please contact Research & Knowledge Exchange Services on 0141 548 3707 or email rkes@strath.ac.uk